The new technology route of Ai Mei vaccines has two major heavyweight vaccine products that have received clinical approval.

ShangHai Securities NewsDec 20 22:00

Annual Review | The 2024 Hong Kong IPO rankings have been released! Mao Ge Ping and Lao Pu Gold surged over 70% on debut! Jingwei Tiandi made a spectacular profit of 6,560 HKD.

Hong Kong, as one of the important Global international financial centers, has been the largest Global IPO financing center seven times since 2009.

Futu NewsDec 20 18:30

The Aimee vaccine / Baked Biological Type II Herpes Simplex Virus mRNA vaccine has been approved for clinical trials.

China Internet FinanceDec 20 12:42

The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."

In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.

cls.cnDec 19 22:27

On the first day of trading for new shares | The subscription amount for Futu reached 31.1 billion! The annual "over-subscription king" Herbs Generation Group Holdings Limited opened high, rising over 25%, with the highest profit of 1800 HKD per lot in th

Futu News reported on December 19 that Herbs Generation Group Holdings Limited opened high on its first day, rising by 25.07%. As of the time of publication, its price was 4.69 Hong Kong dollars, with a transaction amount of 83.0369 million Hong Kong dollars and a total market value of 0.625 billion Hong Kong dollars.

Futu NewsDec 19 09:26

Valued at 2 billion dollars! HANSOH PHARMA grants Merck exclusive global licensing rights for the oral weight loss drug.

① Merck and HANSOH PHARMA in China signed a $2 billion agreement to develop and sell the experimental oral weight loss drug HS-10535, which has effects similar to Wegovy and Zepbound; ② HANSOH PHARMA granted Merck global exclusive licensing rights for HS-10535, receiving an initial payment of $0.112 billion and up to $1.9 billion in milestone payments, along with royalties based on product sales.

cls.cnDec 18 22:08